4157.TWO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 01:30):

Stats
Today's Volume	2.05M
Average Volume	2.44M
Market Cap	11.05B
EPS	TWD0 ( 2024-03-20 )
Next earnings date	( TWD0 ) 2024-05-09
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	81.05
ATR14	TWD0.0470 (0.30%)

Volume Correlation

Long: -0.01 (neutral)

Short: 0.92 (very strong)

Signal:(58.043) Expect same movement, but be aware

TaiGen Biopharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TaiGen Biopharmaceuticals Correlation - Currency/Commodity

0.36
( neutral )

0.16
( neutral )

0.00
( neutral )

-0.19
( neutral )

0.00
( neutral )

-0.78
( moderate negative )

TaiGen Biopharmaceuticals Financials

Annual	2023
Revenue:	TWD123.13M
Gross Profit:	TWD84.08M (68.28 %)
EPS:	TWD0.190

FY	2023
Revenue:	TWD123.13M
Gross Profit:	TWD84.08M (68.28 %)
EPS:	TWD0.190

FY	2022
Revenue:	TWD36.23M
Gross Profit:	TWD32.49M (89.69 %)
EPS:	TWD-0.330

FY	2021
Revenue:	TWD1.29B
Gross Profit:	TWD1.28B (99.02 %)
EPS:	TWD1.080

Financial Reports:

No articles found.

TaiGen Biopharmaceuticals

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.